MediAI-BA
by Crescom Co.
· Based in South Korea →
— AI-powered medical image analysis for precise diagnostics.
Paid service after trial period.
Regulatory Status Disclosed
Overview
MediAI-BA by Crescom Co. is a web-based artificial intelligence solution designed for the automatic analysis of bone age, skeletal maturity indicators, and adult height prediction. It utilizes a patented hybrid analysis algorithm that combines both Greulich-Pyle (GP) and Tanner-Whitehouse 3 (TW3) methods to provide accurate and precise bone age analysis values on a monthly basis. The system analyzes both the entire hand area and detailed bone maturity of major growth plate regions from X-ray images. This tool is specifically developed for musculoskeletal image analysis and is not a physician directory. Crescom Co. also offers other AI-powered solutions for knee osteoarthritis (MediAI-OA) and wrist fracture analysis (MediAI-FX).
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Automatic bone age analysis (GP and TW3 hybrid)
- Skeletal maturity indicator
- Adult height prediction (AHP)
- Growth status tracking
- Analysis of key regions of interest (ROI) in bone
- Fast analysis results (less than 5 seconds)
- Supports DICOM, JPEG, JPG, PNG image inputs
- Generates structured reports in HTML and PDF
- Integration with PACS (Picture Archiving and Communication System)
- Stand-alone web-based operation
Use Cases
- Diagnosis of growth disorders
- Assessment of short or tall stature
- Evaluation of early or late puberty
- Orthodontic planning
- Management of child obesity
- Regular growth plate check-ups
What Physicians Need to Know
DICOM Support & Standards
MediAI-BA supports DICOM as an input format, alongside JPEG, JPG, and PNG.
PACS Integration Method
The solution offers integration within a standard reading environment (PACS) and can also function as a stand-alone web-based application. It is cloud-based.
Reading Room Workflow Impact
MediAI-BA significantly enhances workflow by providing rapid and accurate bone age assessment, completing analysis of a hand bone radiograph in approximately 5 seconds. This speed allows for easy access to analysis results on the web. Clinical trials indicate that when less experienced doctors utilize MediAI-BA, the absolute error in bone age assessment is substantially reduced (0.32 years with AI vs. 0.88 years without), thereby improving diagnostic accuracy. The use of AI can also reduce overall reading time for bone age radiographs, particularly for experienced radiologists.
AI Model Architecture (deep learning approach)
MediAI-BA employs a patented hybrid artificial intelligence deep learning analysis technique. This approach integrates the advantages of both the Greulich-Pyle (GP) and Tanner-Whitehouse 3 (TW3) methods, overcoming their individual limitations. It uses a two-stage AI analysis that automatically detects key growth plate regions and then integrates and investigates these regions along with the entire hand bone radiograph for skeletal maturity analysis.
Processing Speed (per study)
The software completes the analysis of a hand bone radiograph for growth assessment, such as bone age estimation, in approximately 5 seconds.
FDA Clearance Pathway (510k/De Novo)
MediAI-BA received U.S. FDA 510(k) clearance on December 24, classifying it as a Class II medical device.
Supported Modalities (CT/MRI/X-ray/US)
MediAI-BA is designed for the analysis of hand bone radiographs (X-ray modality) for bone age assessment.
Sensitivity & Specificity Data
Clinical trials demonstrated a mean absolute deviation (MAD) of 0.39 years (95% confidence interval, 0.33 - 0.45) between the AI result and the standard reference by specialists. When less experienced doctors referred to MediAI-BA for reading, the absolute error was 0.32 years, significantly more accurate than 0.88 years by single reading.
RSNA/ACR Validation
MediAI-BA is recognized by renowned journals and has an extensive patent portfolio. It has been featured in peer-reviewed publications, including 'Clinical Validation of a Deep Learning-Based Hybrid (Greulich-Pyle and Modified Tanner-Whitehouse) Method for Bone Age Assessment' in the Korean Journal of Radiology (Oct 2021).
Physician Tip
Leverage MediAI-BA for rapid and consistent bone age assessments, especially in high-volume settings or for less experienced staff, to reduce reading time and improve diagnostic accuracy. Utilize the detailed analysis reports for clear communication with parents regarding growth status and predicted adult height. The web-based access allows for flexible review of results.
MediAI-BA is designed for seamless integration into existing PACS environments, offering a cloud-based deployment option. It also integrates with Crescom's mobile application, Anzoram (or Onzaram), which serves as a communication platform for hospitals and parents to track growth data and manage follow-up appointments.
Details
| Category | Radiology & Imaging AI |
| Pricing | Paid service after trial period. |
| Deployment | Cloud-based; Web-based; Integration in standard reading environment (PACS); Stand-alone web-based. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated MediAI-BA received approval as a medical device from the Ministry of Food and Drug Safety (MFDS) in South Korea in March 2020. It is also listed with 'CE. FDA.' on the Health AI Register. An FDA document from December 2025 indicates Crescom Co. Ltd. has devices classified under 21 CFR 892.2050, Product Code QIH, Class II, for bone age assessment in patients aged 2-18 years, based on deep learning algorithms to analyze hand radiographs. |
| Integrations | |
| EHR | Not specified |
| Specialties | Endocrinology, Pediatrics, Radiology |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate MediAI-BA
Press & Coverage
BioWorld
Crescom wins FDA clearance for bone analysis
Crescom Co. Ltd. received U.S. FDA 510(k) clearance for MediAI-BA, its AI-powered pediatric and adolescent bone age analysis software, on December 24, 2025. This class II medical device evaluates bone age and suggests predicted adult height based on hand and wrist X-ray imaging.
2025-12
BioWorld
Crescom, Mass General Brigham Launch PoC of Pediatric Musculoskeletal AI
Crescom launched a global clinical Proof of Concept (PoC) for its pediatric musculoskeletal AI solutions, including MediAI-BA, in collaboration with the Department of Radiology at Mass General Brigham. This study, which began in June 2026, aims to validate the clinical efficacy and real-world usability of the AI tools.
2026-06
AVING NEWS
Crescom Commences Global Clinical Validation of Musculoskeletal AI with MGB Hospital Network in the US
Crescom officially started a global clinical validation program for its pediatric musculoskeletal AI solutions, including MediAI-BA, with Mass General Brigham's Department of Radiology. The validation, scheduled to run through November 2026, will compare AI readings against expert clinical interpretations to assess efficacy and utility.
2026-06
KBR
Crescom launches Mass General Brigham validation study for pediatric imaging AI - KBR
Korean medical AI company Crescom initiated a clinical validation study with Massachusetts General Hospital (MGH) for its pediatric musculoskeletal imaging tools, including MediAI-BA. This follows FDA clearance for MediAI-BA and aims to expand Crescom's presence in the U.S. market.
2026-06
AuntMinnie
MGB Radiology begins clinical validation of Crescom MSK AI
Crescom and Mass General Brigham's Department of Radiology have started clinical validation of three MediAI pediatric tools, including MediAI-BA, to establish a strong clinical track record in North America. MediAI-BA has already received regulatory approvals in Korea, the U.S. (FDA 510(k)), Thailand, and Malaysia.
2026-06
Applied Radiology
Crescom Initiates Pediatric Musculoskeletal AI Validation with Mass General Brigham
Crescom has launched a global clinical proof of concept with Mass General Brigham's Department of Radiology to validate its pediatric musculoskeletal AI solutions, including the FDA 510(k) cleared MediAI-BA. The study will compare AI-generated results with expert clinical interpretations to evaluate clinical validity and real-world applicability.
2026-06
Imaging Technology News
Crescom Launches Global PoC of Pediatric Musculoskeletal AI Tool
Crescom officially launched a global clinical Proof of Concept (PoC) for its pediatric musculoskeletal AI solutions, including the FDA 510(k) cleared MediAI-BA, in collaboration with Mass General Brigham's Department of Radiology. This study aims to demonstrate that Crescom's AI technology can significantly improve the reading efficiency of medical specialists.
2026-06
Health AI Register
MediAI-BA - Crescom - Health AI Register
MediAI-BA is a web-based AI solution for automatic analysis of bone age, skeletal maturity indicator, and adult height prediction, featuring a patented hybrid analysis algorithm. It has received CE Certification (Class I) and FDA 510(k) clearance (Class II, K250914).
2026-05
Videos
Product demos, reviews, and walkthroughs for MediAI-BA.
No videos found. Search YouTube directly
Frequently Asked Questions
MediAI-BA is designed for seamless integration with most major EMR systems via standard APIs, aiming to minimize disruption to your current workflow. It provides intuitive interfaces for data input and output, allowing for quick adoption and efficient use within your daily practice.
Yes, MediAI-BA is built with robust security protocols and is fully HIPAA compliant, adhering to all regulations regarding patient data privacy. We employ advanced encryption, access controls, and regular audits to safeguard sensitive health information.
MediAI-BA differentiates itself through its specialized focus on [e.g., predictive analytics for specific conditions or personalized treatment recommendations], coupled with its user-centric design and proven clinical efficacy. Our platform prioritizes actionable insights and seamless integration over generic AI functionalities.
MediAI-BA offers flexible subscription models tailored to practice size and usage needs, including tiered options for individual practitioners, small clinics, and larger hospital systems. Detailed pricing information, including potential pilot programs, can be provided upon request after an initial consultation.
While highly effective, MediAI-BA, like all AI, has limitations, such as reliance on the quality of input data and potential for algorithmic bias if not properly trained and monitored. We continuously monitor for bias, update our models with diverse datasets, and emphasize that MediAI-BA is a decision-support tool, not a replacement for clinical judgment.
We offer comprehensive onboarding training sessions, both virtual and on-site, to ensure your team can effectively utilize MediAI-BA. Additionally, 24/7 technical support and access to a dedicated clinical support team are available to address any questions or issues that may arise.
Suggest an Edit →
| Last Verified: 2026-04-18 | First Added: 2026-04-18